AstraZeneca (NYSE: AZN) has agreed to invest $2.0 billion in Summit Therapeutics (NASDAQ: SMMT) through the purchase of convertible preferred ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE